Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
11
CDT Quote, Financials, Valuation and Earnings
Last price:
$2.21
Seasonality move
:
-51.38%
Day range:
$2.13 - $2.27
52-week range:
$2.13 - $622.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.65x
Volume:
149.1K
Avg. volume:
589.6K
1-year change:
-99.42%
Market cap:
$1.7M
Revenue:
--
EPS (TTM):
-$237.75
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Conduit Pharmaceuticals has -- downside to fair value with a price target of -- per share.
CDT vs. S&P 500
-
Over the past 5 trading days, Conduit Pharmaceuticals has underperformed the S&P 500 by -7.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Conduit Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Conduit Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Conduit Pharmaceuticals reported revenues of --.
Earnings Growth
-
Conduit Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Conduit Pharmaceuticals reported earnings per share of -$19.80.
Enterprise value:
2.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$4.4M | -$6.7M | -$16.2M | -$3M | -$4M | |
| EBITDA | -$6M | $1.2M | -$17.2M | -$3.4M | -$4.8M | |
| Diluted EPS | -$124.40 | -$136.85 | -$237.75 | -$72.15 | -$19.80 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $8K | $3.2M | $5.9M | |
| Total Assets | -- | -- | $13K | $4.9M | $7.3M | |
| Current Liabilities | -- | -- | $3.8M | $2M | $4.5M | |
| Total Liabilities | -- | -- | $12.5M | $8M | $4.6M | |
| Total Equity | -- | -- | -$12.5M | -$3.1M | $2.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$8.1M | -$11.7M | -$2.4M | -$4.3M | |
| Cash From Investing | -- | $968K | -$47K | -- | -$4K | |
| Cash From Financing | -- | $8.7M | $12M | -- | $5.9M | |
| Free Cash Flow | -- | -$8.1M | -$11.7M | -$2.4M | -$4.3M | |
CDT
Sector
Market Cap
$1.7M
$34.4M
Price % of 52-Week High
0.35%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-99.42%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.35
200-day SMA
Sell
Level
$64.03
Bollinger Bands (100)
Sell
Level
2.91 - 13.63
Chaikin Money Flow
Sell
Level
-95.5M
20-day SMA
Sell
Level
$2.47
Relative Strength Index (RSI14)
Sell
Level
31.69
ADX Line
Sell
Level
21.49
Williams %R
Buy
Level
-93.4783
50-day SMA
Sell
Level
$3.62
MACD (12, 26)
Sell
Level
-0.41
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
102.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor, and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Stock Forecast FAQ
In the current month, CDT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CDT average analyst price target in the past 3 months is --.
-
Where Will Conduit Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Conduit Pharmaceuticals share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Conduit Pharmaceuticals?
Analysts are divided on their view about Conduit Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Conduit Pharmaceuticals is a Sell and believe this share price will rise from its current level to --.
-
What Is Conduit Pharmaceuticals's Price Target?
The price target for Conduit Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CDT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Conduit Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CDT?
You can purchase shares of Conduit Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Conduit Pharmaceuticals shares.
-
What Is The Conduit Pharmaceuticals Share Price Today?
Conduit Pharmaceuticals was last trading at $2.21 per share. This represents the most recent stock quote for Conduit Pharmaceuticals. Yesterday, Conduit Pharmaceuticals closed at $2.19 per share.
-
How To Buy Conduit Pharmaceuticals Stock Online?
In order to purchase Conduit Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
